文献速递前列腺癌

达罗他胺联合雄激素剥夺治疗和多西他赛治疗高或低肿瘤负荷转移性激素敏感性前列腺癌患者的前列腺特异性抗原深度持久缓解及其与临床结局的关联:随机3期ARASENS研究分析

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
PubMed 文献 · Eur Urol · 2024-04-21

ARASENS研究纳入转移性激素敏感性前列腺癌患者,随机接受达罗他胺600mg每日两次(n=651)或安慰剂(n=654),均联合ADT和多西他赛。达罗他胺组任意时间不可测PSA比例在总人群为67% vs 29%,高瘤负荷亚组62% vs 26%,低瘤负荷亚组84% vs 38%;达罗他胺延迟PSA进展,总人群HR 0.26(95%CI 0.21-0.31)。24周时不可测PSA与更长OS相关,达罗他胺组HR 0.49(95%CI 0.37-0.65)。

要点

  • 达罗他胺+ADT+多西他赛使高或低瘤负荷mHSPC患者获得深度持久PSA缓解。
  • 任意时间不可测PSA比例达罗他胺组67% vs 安慰剂组29%(总人群)。
  • 达罗他胺延迟PSA进展,总人群HR 0.26(95%CI 0.21-0.31)。

核心结论

  • 达罗他胺+ADT+多西他赛使高或低瘤负荷mHSPC患者获得深度且持久的PSA缓解。
  • 达到不可测PSA(<0.2 ng/ml)与更好的临床结局相关。

研究设计与样本

  • ARASENS为国际、双盲、3期研究(NCT02799602),纳入转移性激素敏感性前列腺癌患者。
  • 患者随机接受达罗他胺600 mg口服每日两次(n=651)或安慰剂(n=654),均联合ADT+多西他赛。

主要发现

  • 任意时间不可测PSA比例达罗他胺组 vs 安慰剂组:总人群67% vs 29%,高瘤负荷亚组62% vs 26%,低瘤负荷亚组84% vs 38%。
  • PSA进展时间达罗他胺组 vs 安慰剂组HR:总人群0.26(95%CI 0.21-0.31),高瘤负荷亚组0.30(95%CI 0.24-0.37),低瘤负荷亚组0.093(95%CI 0.047-0.18)。
  • 24周时不可测PSA与更长OS相关,达罗他胺组HR 0.49(95%CI 0.37-0.65),并与更长至CRPC时间和至PSA进展时间相关,疾病负荷亚组结果相似。

关键数值与推荐

  • 不可测PSA定义为<0.2 ng/ml。
  • PSA进展定义为较最低值相对升高≥25%且绝对升高≥2 ng/ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Addition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. METHODS: ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel. The proportion of patients with undetectable PSA (<0.2 ng/ml) and time to PSA progression (≥25% relative and ≥2 ng/ml absolute increase from nadir) were compared between groups in prespecified exploratory analyses. PSA outcomes by disease volume and the association of undetectable PSA with OS and times to castration-resistant prostate cancer (CRPC) and PSA progression were assessed in post hoc analyses. KEY FINDINGS AND LIMITATIONS: The proportion of patients with undetectable PSA at any time was more than doubled with darolutamide versus placebo, at 67% versus 29% in the overall population, 62% versus 26% in the high-volume subgroup, and 84% versus 38% in the low-volume subgroup. Darolutamide delayed time to PSA progression versus placebo, with hazard ratios of 0.26 (95% confidence interval [CI] 0.21-0.31) in the overall population, 0.30 (95% CI 0.24-0.37) in the high-volume subgroup, and 0.093 (95% CI 0.047-0.18) in the low-volume subgroup. Undetectable PSA at 24 wk was associated with longer OS, with a hazard ratio of 0.49 (95% CI 0.37-0.65) in the darolutamide group, as well as longer times to CRPC and PSA progression, with similar findings in the disease volume subgroups. CONCLUSIONS AND CLINICAL IMPLICATIONS: Darolutamide + ADT + docetaxel led to deep and durable PSA responses in patients with high- or low-volume mHSPC. Achievement of undetectable PSA (<0.2 ng/ml) was correlated with better clinical outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Saad F, Hussain MHA, Tombal B, et al. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. Eur Urol. 2024. PMID: 38644146. doi:10.1016/j.eururo.2024.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。